ProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buying

  • The stock of the day on Tuesday was ProKidney Corp.'s, as it was both the biggest gainer and the most actively traded on major U.S. exchanges, after the biotechnology company's diabetes treatment produced positive results in a mid-stage trial.